Celera Genomics Reports Fourth Quarter And Fiscal 2006 Results

ROCKVILLE, Md.--(BUSINESS WIRE)--July 27, 2006--Celera Genomics Group (NYSE:CRA - News), an Applera Corporation business, today reported a net loss of $5.3 million, or $0.07 per share, for the fourth quarter of fiscal 2006 ended June 30, 2006, compared to a net loss of $16.4 million, or $0.22 per share, for the fourth quarter of fiscal 2005. The fourth quarter 2006 results included a $5.3 million pre-tax charge for restructuring costs associated with the previously announced decision to partner or sell the small molecule drug discovery and development programs and the integration of Celera Diagnostics into Celera Genomics. The fourth quarter 2006 results also included a pre-tax gain of $8.6 million from the sale of certain small molecule drug discovery and development programs. Results for the fourth quarter of fiscal 2005 included a pre-tax favorable adjustment of $3.6 million associated with the sale of Celera's Rockville, MD facility, a tax benefit of $2.2 million related to additional U.S. R&D credits, and a $3.4 million pre-tax charge for severance and asset impairments related to the discontinuation of the Online/Information Business. All per share amounts refer to Applera Corporation-Celera Genomics Group Common Stock.